DNL 126
Alternative Names: DNL-126; ETV:N-sulphoglucosamine sulphohydrolase; ETV:SGSH; Recombinant sulphoglucosamine sulphohydrolase - Denali TherapeuticsLatest Information Update: 24 Nov 2025
At a glance
- Originator Denali Therapeutics Inc
- Class Hydrolases; Recombinant fusion proteins
- Mechanism of Action N-sulfoglucosamine sulfohydrolase replacements
-
Orphan Drug Status
Yes - Mucopolysaccharidosis III
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Mucopolysaccharidosis III
Highest Development Phases
- Phase I/II Mucopolysaccharidosis III
Most Recent Events
- 23 Sep 2025 Denali Therapeutics completes enrolment in a phase-I/II trial in Mucopolysaccharidosis III (In adolescents, In children, In infants) in USA (IV) (NCT06181136)
- 11 Aug 2025 Denali Therapeutics align with US FDA for accelerated approval of DNL 126 for Mucopolysaccharidosis III
- 11 Aug 2025 Denali Therapeutics plans phase-III trial for Mucopolysaccharidosis III